Cargando…

Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas

BACKGROUND: High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a promising approach for lymphomas. This study aimed to evaluate the effect of ifosfamide, cisplatin or carboplatin, and etoposide (ICE)-based regimen as a mobilization regimen on relapsed, refractory, or h...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Ping, Liu, Peng, Zhou, Sheng-Yu, He, Xiao-Hui, Han, Xiao-Hong, Qin, Yan, Yang, Sheng, Zhang, Chang-Gong, Gui, Lin, Yao, Jia-Rui, Zhao, Li-Ya, Zhang, Shu-Xiang, Sun, Yan, Shi, Yuan-Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4725560/
https://www.ncbi.nlm.nih.gov/pubmed/26365969
http://dx.doi.org/10.4103/0366-6999.164936
_version_ 1782411648493944832
author Zhou, Ping
Liu, Peng
Zhou, Sheng-Yu
He, Xiao-Hui
Han, Xiao-Hong
Qin, Yan
Yang, Sheng
Zhang, Chang-Gong
Gui, Lin
Yao, Jia-Rui
Zhao, Li-Ya
Zhang, Shu-Xiang
Sun, Yan
Shi, Yuan-Kai
author_facet Zhou, Ping
Liu, Peng
Zhou, Sheng-Yu
He, Xiao-Hui
Han, Xiao-Hong
Qin, Yan
Yang, Sheng
Zhang, Chang-Gong
Gui, Lin
Yao, Jia-Rui
Zhao, Li-Ya
Zhang, Shu-Xiang
Sun, Yan
Shi, Yuan-Kai
author_sort Zhou, Ping
collection PubMed
description BACKGROUND: High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a promising approach for lymphomas. This study aimed to evaluate the effect of ifosfamide, cisplatin or carboplatin, and etoposide (ICE)-based regimen as a mobilization regimen on relapsed, refractory, or high-risk aggressive lymphoma. METHODS: From June 2001 to May 2013, patients with lymphomas who mobilized by ICE-based regimen for ASCT were analyzed in this retrospective study. The results of the autologous peripheral blood stem cells collection, toxicity, engraftment after ICE-based mobilization regimen were analyzed in this study. Furthermore, risk factors for overall survival (OS) and progression free survival (PFS) were evaluated by univariate analysis. RESULTS: The stem cells were mobilized using ICE-based regimen plus rituximab or ICE-based regimen alone in 12 patients and 54 patients, respectively. The results of stem cell mobilization were excellent. Ninety-seven percentages of the patients had the stem cell collection of at least 2.0 × 10(6) CD34(+) cells/kg and 68% had at least 5 × 10(6) CD34(+) cells/kg. Fifty-eight percentage of the patients experienced Grade 4 neutropenia, 20% developed febrile neutropenia, and only 12% had Grade 4 thrombocytopenia. At a median follow-up of 63.8 months, the 5-year PFS and OS were 64.4% and 75.3%, respectively. CONCLUSION: ICE is a powerful regimen for stem cell mobilization in patients with lymphomas.
format Online
Article
Text
id pubmed-4725560
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-47255602016-04-04 Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas Zhou, Ping Liu, Peng Zhou, Sheng-Yu He, Xiao-Hui Han, Xiao-Hong Qin, Yan Yang, Sheng Zhang, Chang-Gong Gui, Lin Yao, Jia-Rui Zhao, Li-Ya Zhang, Shu-Xiang Sun, Yan Shi, Yuan-Kai Chin Med J (Engl) Original Article BACKGROUND: High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a promising approach for lymphomas. This study aimed to evaluate the effect of ifosfamide, cisplatin or carboplatin, and etoposide (ICE)-based regimen as a mobilization regimen on relapsed, refractory, or high-risk aggressive lymphoma. METHODS: From June 2001 to May 2013, patients with lymphomas who mobilized by ICE-based regimen for ASCT were analyzed in this retrospective study. The results of the autologous peripheral blood stem cells collection, toxicity, engraftment after ICE-based mobilization regimen were analyzed in this study. Furthermore, risk factors for overall survival (OS) and progression free survival (PFS) were evaluated by univariate analysis. RESULTS: The stem cells were mobilized using ICE-based regimen plus rituximab or ICE-based regimen alone in 12 patients and 54 patients, respectively. The results of stem cell mobilization were excellent. Ninety-seven percentages of the patients had the stem cell collection of at least 2.0 × 10(6) CD34(+) cells/kg and 68% had at least 5 × 10(6) CD34(+) cells/kg. Fifty-eight percentage of the patients experienced Grade 4 neutropenia, 20% developed febrile neutropenia, and only 12% had Grade 4 thrombocytopenia. At a median follow-up of 63.8 months, the 5-year PFS and OS were 64.4% and 75.3%, respectively. CONCLUSION: ICE is a powerful regimen for stem cell mobilization in patients with lymphomas. Medknow Publications & Media Pvt Ltd 2015-09-20 /pmc/articles/PMC4725560/ /pubmed/26365969 http://dx.doi.org/10.4103/0366-6999.164936 Text en Copyright: © 2015 Chinese Medical Journal http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Original Article
Zhou, Ping
Liu, Peng
Zhou, Sheng-Yu
He, Xiao-Hui
Han, Xiao-Hong
Qin, Yan
Yang, Sheng
Zhang, Chang-Gong
Gui, Lin
Yao, Jia-Rui
Zhao, Li-Ya
Zhang, Shu-Xiang
Sun, Yan
Shi, Yuan-Kai
Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas
title Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas
title_full Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas
title_fullStr Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas
title_full_unstemmed Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas
title_short Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas
title_sort ifosfamide, cisplatin or carboplatin, and etoposide (ice)-based chemotherapy for mobilization of autologous peripheral blood stem cells in patients with lymphomas
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4725560/
https://www.ncbi.nlm.nih.gov/pubmed/26365969
http://dx.doi.org/10.4103/0366-6999.164936
work_keys_str_mv AT zhouping ifosfamidecisplatinorcarboplatinandetoposideicebasedchemotherapyformobilizationofautologousperipheralbloodstemcellsinpatientswithlymphomas
AT liupeng ifosfamidecisplatinorcarboplatinandetoposideicebasedchemotherapyformobilizationofautologousperipheralbloodstemcellsinpatientswithlymphomas
AT zhoushengyu ifosfamidecisplatinorcarboplatinandetoposideicebasedchemotherapyformobilizationofautologousperipheralbloodstemcellsinpatientswithlymphomas
AT hexiaohui ifosfamidecisplatinorcarboplatinandetoposideicebasedchemotherapyformobilizationofautologousperipheralbloodstemcellsinpatientswithlymphomas
AT hanxiaohong ifosfamidecisplatinorcarboplatinandetoposideicebasedchemotherapyformobilizationofautologousperipheralbloodstemcellsinpatientswithlymphomas
AT qinyan ifosfamidecisplatinorcarboplatinandetoposideicebasedchemotherapyformobilizationofautologousperipheralbloodstemcellsinpatientswithlymphomas
AT yangsheng ifosfamidecisplatinorcarboplatinandetoposideicebasedchemotherapyformobilizationofautologousperipheralbloodstemcellsinpatientswithlymphomas
AT zhangchanggong ifosfamidecisplatinorcarboplatinandetoposideicebasedchemotherapyformobilizationofautologousperipheralbloodstemcellsinpatientswithlymphomas
AT guilin ifosfamidecisplatinorcarboplatinandetoposideicebasedchemotherapyformobilizationofautologousperipheralbloodstemcellsinpatientswithlymphomas
AT yaojiarui ifosfamidecisplatinorcarboplatinandetoposideicebasedchemotherapyformobilizationofautologousperipheralbloodstemcellsinpatientswithlymphomas
AT zhaoliya ifosfamidecisplatinorcarboplatinandetoposideicebasedchemotherapyformobilizationofautologousperipheralbloodstemcellsinpatientswithlymphomas
AT zhangshuxiang ifosfamidecisplatinorcarboplatinandetoposideicebasedchemotherapyformobilizationofautologousperipheralbloodstemcellsinpatientswithlymphomas
AT sunyan ifosfamidecisplatinorcarboplatinandetoposideicebasedchemotherapyformobilizationofautologousperipheralbloodstemcellsinpatientswithlymphomas
AT shiyuankai ifosfamidecisplatinorcarboplatinandetoposideicebasedchemotherapyformobilizationofautologousperipheralbloodstemcellsinpatientswithlymphomas